Asfotase alfa in hypophosphatasia in children and adolescents: survival advantage for small children

15 January 2020 - Weak evidence does not allow a specific statement to be made about the extent of the added ...

Read more →

Larotrectinib in tumours with NTRK gene fusion: data are not yet sufficient for derivation of an added benefit

15 January 2020 - First assessment of a histology-independent drug/studies without control arms. ...

Read more →

Differences in health technology assessment recommendations among European jurisdictions: the role of practice variations

14 January 2020 - HTA recommendations vary widely throughout Europe, even for the same medicine. ...

Read more →

Commission proposal for a European regulation on HTA

29 November 2019 - Europe cannot afford an inefficient system for joint clinical assessments. ...

Read more →

Pembrolizumab in metastatic NSCLC: now added benefit for subpopulations

19 September 2019 - After a methodological uncertainty has been resolved, analyses on overall survival are now usable ...

Read more →

5 people setting EU drug prices

19 September 2019 - Politic’s guide to the policy makers debating how to calculate the cost of cures. ...

Read more →

HTA in the European Union: osteoporosis screening without proof of benefit

16 September 2019 - For the first time, an IQWiG team is in charge of assessing health technology for the ...

Read more →

Germany may have the answer for reducing drug prices

11 September 2019 - American lawmakers attempting to stem spiraling drug costs might find inspiration in Germany, where the government’s ...

Read more →

Dacomitinib in advanced lung cancer: variety of disadvantages lifts survival advantage

 1 August 2019 - Prolonged survival is sometimes accompanied by severe side effects, symptom and quality of life deterioration ...

Read more →

Ezetimibe reduces the risk of heart attacks and strokes

26 July 2019 - Added to existing statin therapy, ezetimibe is preventative in patients with CHD and acute coronary syndrome. ...

Read more →

Evaluation of ethical analyses in seven reports from the European Network for Health Technology Assessment

16 July 2019 - Ethics has been considered among the core domains of health technology assessment, but there are still ...

Read more →

Early benefit assessment reveals weaknesses in the development of new drugs

11 July 2019 - Analysis of 216 AMNOG assessments in the BMJ / Proposals for more targeted drug development ...

Read more →

New drugs: where did we go wrong and what can we do better?

10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...

Read more →

Biomarker-based cancer diagnostics: German pricing regulator sets high validation and reimbursement standards for novel diagnostic methods

10 July 2019 - On 20 June 2019, for the first time, the German Federal Joint Committee (G-BA), made the resolution ...

Read more →

Report calls for European funding reform for gene therapies

8 July 2019 - New payment models, dedicated investment, and better health technology assessment are among a raft of changes ...

Read more →